These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 38506333)

  • 61. An Intranasal OMV-Based Vaccine Induces High Mucosal and Systemic Protecting Immunity Against a SARS-CoV-2 Infection.
    van der Ley PA; Zariri A; van Riet E; Oosterhoff D; Kruiswijk CP
    Front Immunol; 2021; 12():781280. PubMed ID: 34987509
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Salivary and serum IgA and IgG responses to SARS-CoV-2-spike protein following SARS-CoV-2 infection and after immunization with COVID-19 vaccines.
    Li D; Calderone R; Nsouli TM; Reznikov E; Bellanti JA
    Allergy Asthma Proc; 2022 Sep; 43(5):419-430. PubMed ID: 36065108
    [No Abstract]   [Full Text] [Related]  

  • 63. Cross-Reactive Antibody Responses to Coronaviruses Elicited by SARS-CoV-2 Infection or Vaccination.
    Lee RSH; Cheng SMS; Zhao J; Tsoi AYS; Lau KKM; Chan CHC; Li JKC; Hui DSC; Peiris M; Yen HL
    Influenza Other Respir Viruses; 2024 May; 18(5):e13309. PubMed ID: 38725111
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Neutralizing-antibody-independent SARS-CoV-2 control correlated with intranasal-vaccine-induced CD8
    Ishii H; Nomura T; Yamamoto H; Nishizawa M; Thu Hau TT; Harada S; Seki S; Nakamura-Hoshi M; Okazaki M; Daigen S; Kawana-Tachikawa A; Nagata N; Iwata-Yoshikawa N; Shiwa N; Suzuki T; Park ES; Ken M; Onodera T; Takahashi Y; Kusano K; Shimazaki R; Suzaki Y; Ami Y; Matano T
    Cell Rep Med; 2022 Feb; 3(2):100520. PubMed ID: 35233545
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection.
    Gallais F; Gantner P; Bruel T; Velay A; Planas D; Wendling MJ; Bayer S; Solis M; Laugel E; Reix N; Schneider A; Glady L; Panaget B; Collongues N; Partisani M; Lessinger JM; Fontanet A; Rey D; Hansmann Y; Kling-Pillitteri L; Schwartz O; De Sèze J; Meyer N; Gonzalez M; Schmidt-Mutter C; Fafi-Kremer S
    EBioMedicine; 2021 Sep; 71():103561. PubMed ID: 34455390
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Mucosal antibody responses to SARS-CoV-2 booster vaccination and breakthrough infection.
    Bhavsar D; Singh G; Sano K; Gleason C; Srivastava K; ; Carreno JM; Simon V; Krammer F
    mBio; 2023 Dec; 14(6):e0228023. PubMed ID: 38092666
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Neutralizing antibodies in milk and blood of lactating women vaccinated for SARS-CoV-2: a systematic review.
    Vieira ISA; Rocha FMD; Vilarim M; Rebelo F; Marano D
    Rev Paul Pediatr; 2024; 43():e2023210. PubMed ID: 39258663
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Impact of maternal SARS-CoV-2 booster vaccination on blood and breastmilk antibodies.
    Rick AM; Lentscher A; Xu L; Wilkins MS; Nasser A; Tuttle DJ; Megli C; Marques ETA; McElroy AK; Williams JV; Martin JM
    PLoS One; 2023; 18(6):e0287103. PubMed ID: 37310982
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The Secretory IgA Response in Human Milk Against the SARS-CoV-2 Spike Is Highly Durable and Neutralizing for At Least 1 Year of Lactation Postinfection.
    Yang X; Fox A; DeCarlo C; Pineda N; Powell RLR
    Breastfeed Med; 2023 Aug; 18(8):602-611. PubMed ID: 37615565
    [No Abstract]   [Full Text] [Related]  

  • 70. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.
    Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR
    Front Immunol; 2022; 13():827306. PubMed ID: 35173736
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Specific IgA, But Not IgG, in Human Milk From COVID-19-Infected Mothers Neutralizes SARS-CoV-2.
    Macchiaverni P; Lloyd M; Masters L; Divakara N; Panta K; Imrie A; Sánchez-García L; Pellicer A; Rodriguez JM; Verhasselt V
    Pediatr Infect Dis J; 2024 Jun; 43(6):532-535. PubMed ID: 38421196
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Hybrid immunity to SARS-CoV-2 arises from serological recall of IgG antibodies distinctly imprinted by infection or vaccination.
    Voss WN; Mallory MA; Byrne PO; Marchioni JM; Knudson SA; Powers JM; Leist SR; Dadonaite B; Townsend DR; Kain J; Huang Y; Satterwhite E; Castillo IN; Mattocks M; Paresi C; Munt JE; Scobey T; Seeger A; Premkumar L; Bloom JD; Georgiou G; McLellan JS; Baric RS; Lavinder JJ; Ippolito GC
    Cell Rep Med; 2024 Aug; 5(8):101668. PubMed ID: 39094579
    [TBL] [Abstract][Full Text] [Related]  

  • 73. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
    Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y
    Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Durability of COVID-19 humoral immunity post infection and different SARS-COV-2 vaccines.
    Alroqi F; Barhoumi T; Masuadi E; Nogoud M; Aljedaie M; Abu-Jaffal AS; Bokhamseen M; Saud M; Hakami M; Arabi YM; Nasr A
    J Infect Public Health; 2024 Apr; 17(4):704-711. PubMed ID: 38479067
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine.
    Duarte LF; Gálvez NMS; Iturriaga C; Melo-González F; Soto JA; Schultz BM; Urzúa M; González LA; Vázquez Y; Ríos M; Berríos-Rojas RV; Rivera-Pérez D; Moreno-Tapia D; Pacheco GA; Vallejos OP; Hoppe-Elsholz G; Navarrete MS; Rojas Á; Fasce RA; Fernández J; Mora J; Ramírez E; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Bueno SM; Kalergis AM
    Front Immunol; 2021; 12():742914. PubMed ID: 34659237
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
    Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
    Front Immunol; 2021; 12():802858. PubMed ID: 35003131
    [TBL] [Abstract][Full Text] [Related]  

  • 77. SARS-CoV-2 Antibodies in Human Milk After mRNA and Adenovector-Based Vaccination: A Systematic Review and Meta-Analysis.
    Li X; Hu Y; Lv Y; Obore N; Wang Y; Yu H
    J Hum Lact; 2024 Aug; 40(3):425-433. PubMed ID: 38798078
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Durable antibody and effector memory T cell responses in breastmilk from women with SARS-CoV-2.
    Narayanaswamy V; Pentecost BT; Telfer JC; Burnside AS; Schneider SS; Alfandari D; Baker RL; Saiju A; Nodiff S; Arcaro KF
    Front Immunol; 2022; 13():985226. PubMed ID: 36172379
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Receptor-binding Domain Severe Acute Respiratory Syndrome Coronavirus 2-specific Antibodies in Human Milk From Mothers With Coronavirus Disease 2019 Polymerase Chain Reaction or With Symptoms Suggestive of Coronavirus Disease 2019.
    Demers-Mathieu V; DaPra C; Fels S; Medo E
    J Pediatr Gastroenterol Nutr; 2021 Jul; 73(1):125-128. PubMed ID: 33938523
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Kinetics of SARS-CoV-2 Specific and Neutralizing Antibodies over Seven Months after Symptom Onset in COVID-19 Patients.
    Zhu L; Xu X; Zhu B; Guo X; Xu K; Song C; Fu J; Yu H; Kong X; Peng J; Huang H; Zou X; Ding Y; Bao C; Zhu F; Hu Z; Wu M; Shen H
    Microbiol Spectr; 2021 Oct; 9(2):e0059021. PubMed ID: 34550000
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.